Emerging Paediatric Uses of Dupilumab Beyond Approvals
Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia · 2026
Read Emerging Paediatric Uses of Dupilumab Beyond Approvals by Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13630499.txt.
Description
Simone Foti Randazzese and eleven colleagues review the widening off-label use of dupilumab in children, published in 2026. The antibody blocks the shared receptor for two messengers that drive type-2 inflammation, and it already holds approvals spanning eczema, asthma, swollen nasal tissue, and an inflamed oesophagus, some reaching into infancy.
Beyond those licences, case reports and small series describe benefits across inflammatory skin diseases, immune defects with severe allergy, transplant-related immune chaos, selected lung conditions, and food allergy. Reported gains in severity and quality of life come with a reassuring safety picture, yet nearly all evidence is uncontrolled. The authors call for prospective trials to define who benefits, at what dose, and with what long-term safety.
Catalog record
| CREATOR | Simone Foti Randazzese, Anna Calamita, Diletta D'Angelo, Alessia Marseglia, Esther Mesa Lombardero, Sara Pedersoli, Micol Tedeschi, Mara De Amici, Sara Manti, Valeria Brazzelli, Amelia Licari, Gian Luigi Marseglia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48251 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |